Kai Feng

Kai Feng

Auto-generated profile, based on publicly available information

Kai Feng

State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2025 in Chinese Chemical Letters
Verified
Journal Article
Closed access
HZHaolin Zhang
Haolin Zhang
KFKai Feng
Kai Feng
GLGuisen Li
Guisen Li
WCWeijiao Chen
Weijiao Chen
YSYuan Shao
Yuan Shao
PYPeng Yang
Peng Yang

7 July 2024 in ACS Applied Nano Materials
Verified
Journal Article
Closed access
LCLili Chen
Lili Chen
XWXiaojing Wu
Xiaojing Wu
TQTiancheng Qi
Tiancheng Qi
KFKai Feng
Kai Feng
CPCheng Pei
Cheng Pei

15 July 2025 in Ultrasonics Sonochemistry
Verified
Journal Article
Open access
YZYan Zhao
Yan Zhao
KFKai Feng
Kai Feng
BLBoxin Liu
Boxin Liu
ZZZhihao Zhang
Zhihao Zhang
HHHaozhou Huang
Haozhou Huang
BDBin Dong
Bin Dong
Aspirin is an antiplatelet agglutinating drug used clinically for the prevention and treatment of angina pectoris, myocardial infarction, and cerebral thrombosis. In this study, aspirin inhalable powder was prepared by ultrasound-intensified anti-solvent crystallization (UIAC) and developed for rapid antiplatelet aggregation, which could reduce the dose and gastrointestinal irritation. The particle size distribution, morphology, density, fluidity, and in vitro aerodynamic performance of the as-prepared powders were systematically evaluated. Meanwhile, machine learning methodology, specifically utilizing the Decision Tree Regressor in conjunction with Shapley Value analysis, was applied to elucidate the influence of critical process parameters within the production process. The powder flowability could be improved by the addition of excipients L150 and L-leucine (Leu). The value of fine particle fraction (FPF) increased from 10.40 % to 45.86 % when adding L150 (60 %, w/w) and Leu (5 %, w/w). The cytotoxicity study of aspirin inhalable powder was performed at cellular level, and demonstrated aspirin powder had no significant toxic effect. The Calu-3 cell monolayer interfaced to simulate lung epithelial tissue, demonstrated the high permeability of inhalable powder in lung. Pharmacokinetics were investigated in healthy rats, compared with oral administration, the Tmax of inhale administration (10 min) was significantly shorter than oral administration (30 min), and the AUC was 1.91 times higher than that of the oral administration, demonstrating that pulmonary drug delivery accelerated the absorption and increased the bioavailability of aspirin.